



Development of Carbohydrate Based Anticancer Vaccine




Munmun Mukherjee
Group Meeting

Strategy




Design of Carbohydrate-Based antitumor Vaccines

Cell-surface glycoproteins and glycolipids displaying tumor-associated carbohydrate antigen




Malignantly transformed tumor cell exhibit abnormal cell surface glycosylation pattern

Design of Carbohydrate-Based antitumor Vaccines




Mimic the tumor cell surface : vaccine with one or more TACA




Design of Carbohydrate-Based antitumor Vaccines

Evaluation of reactivity of antibodies against cell-surface TACAs



Monovalent Vaccines




Isolated in submilligram quantities as a ceramide-linked glycolipid from the human breast cancer cell line MCF-7 by Hakomori *et al.*

Globo-H was also expressed in other types of carcinomas including colon, lung, ovary, small cell lung cancer, and prostate cancers

Monovalent Clustered Vaccines

Exhibit enhanced levels of antibody induction in comparison with nonclustered congeners




Clustering groups of antigens to single peptide backbone

Cassette method: galactose (Gal)NAc monosaccharide α -linked to amino acid

synthesis of oligosaccharide proceed with preexisting α -O-linkage

Unimolecular Multivalent Vaccines




Unimolecular pentavalent vaccine: mimic heterogeneity


Each antigens except Le^y induced formation of IgM and IgG antibodies.

second generation pentavalent construct involve replacement of Le^y antigen.

General approach to synthetic Carbohydrate Vaccines





Some Antigens in Cancer cell




GalNAc α 1-O-Ser/Thr linkage

T _N	$R^1 = H; R^2 = H$
T	$R^1 = \beta\text{-D-Gal}; R^2 = H$
ST _N	$R^1 = H; R^2 = \alpha\text{-D-NeuAc}$
2,6-ST	$R^1 = \beta\text{-D-Gal}; R^2 = \alpha\text{-D-NeuAc}$




Glycosylation Strategy

Acetal exchange




Glycosylation Strategy


Acetal exchange



Glycal oxidation




First Total Synthesis of Globo-H



Bilodeau,M.T.; Park,T.K.; Hu, S.; Randolph,J.T.; Danishefsky, S.J.; Livingston, P.O.; Zhang,S. *J. Am. Chem. Soc.* **1995**, 117, 7840

First Total Synthesis of Globo-H




Bilodeau,M.T.; Park,T.K.; Hu, S.; Randolph,J.T.; Danishefsky, S.J.; Livingston, P.O.; Zhang,S. *J. Am. Chem. Soc.* **1995**, 117, 7840

First Total Synthesis of Globo-H


a) TBAF, THF, 94%

b) (i) Na, NH₃, THF
(ii) Ac₂O, TEA, THF
DMAP, 85%

c) (i) DMDO, DCM
(ii) Allyl Alcohol, 66%
d) NaOMe, MeOH, >99%




Orthogonal Glycosylation Strategy




Tong Zhu, T.; Boons, G.J. *Angew. Chem. Int. Ed.* **1999**, *38*, 3495
 Galonic, P. D., Gin, Y. D., *Nature* **2007**, *446*, 1000

One-Pot Synthesis Strategy

1. Relative reactivity of various glycerides donors
2. Choice of protecting group




One-Pot Synthesis




Burkhart, F., Zhang, Z., Wacowich-Sgarbi, S.; Wong, C.-H. *Angew. Chem. Int. Ed.* **2001**, *40*, 1274

One-Pot Synthesis




Burkhart, F., Zhang, Z., Wacowich-Sgarbi, S.; Wong, C.-H. *Angew. Chem. Int. Ed.* **2001**, *40*, 1274


End Game



= R



End Game



Conclusion

Organic synthesis ,a powerful tool in getting complex carbohydrate antigens, potential targets for cancer immunotherapy.


investigation of some antigens (Globo-H, ST_N, T_N, T) relies on chemical synthesis

Recently prepared pentavalent neoglycopeptide (to mimic heterogeneity) have shown encouraging antibody response

“Methodological building upon the principles of our science leads to the magic of synthesis –with its unique capability to prepare molecules of virtually any shape and juxtaposition of functional groups. Creative synthesis is the indispensable talent that the chemist will bring to the many exciting struggles and opportunities in the future.” – *Samuel Danishefsky*

Future Direction

(a)



(b)

